1 |
ADRB2
| 9件: Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation | D02147
D02147
|
Salbutamol
| 12件: 3 3, 11, 12, 13, 49, 85, 86, 89, 111, 113, 256, 299 |
2 |
ABAT
| 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, Propanoate metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse | D00399
D00399
|
Valproic acid
| 14件: 2 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256 |
3 |
GABRA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
4 |
GABRA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
5 |
GABRA3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
6 |
GABRA4
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
7 |
GABRA5
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
8 |
GABRA6
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
9 |
GABRB1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
10 |
GABRB2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
11 |
GABRB3
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
12 |
GABRD
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
13 |
GABRE
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
14 |
GABRG1
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
15 |
GABRG2
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
16 |
GABRG3
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
17 |
GABRP
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
18 |
GAD1
| 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus | D00399
D00399
|
Valproic acid
| 14件: 2 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256 |
19 |
GAD2
| 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus | D00399
D00399
|
Valproic acid
| 14件: 2 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256 |
20 |
MSTN
| 1件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction | D11265
D11265
|
Talditercept alfa
| 1件: 3 3 |
21 |
MSTN
| 1件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction | D11797
D11797
|
Apitegromab
| 1件: 3 3 |
22 |
GRIA1
| 14件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
23 |
GRIA2
| 15件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
24 |
GRIA3
| 13件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
25 |
GRIA4
| 10件: cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
26 |
GRIK1
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
27 |
GRIK2
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
28 |
GRIK3
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
29 |
GRIK4
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
30 |
GRIK5
| 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
31 |
GRIN1
| 18件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
32 |
GRIN2A
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
33 |
GRIN2B
| 19件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
34 |
GRIN2C
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
35 |
GRIN2D
| 15件: Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
36 |
NR3C1
| 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00472
D00472
|
Prednisolone
| 42件: 3 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
37 |
AR
| 4件: Oocyte meiosis Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer | D00075
D00075
|
Testosterone
| 8件: 1 1, 2, 3, 13, 60, 76, 78, 113 |
38 |
KCNA4
| 2件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome | D04127
D04127
|
Dalfampridine
| 5件: 3 3, 4, 6, 13, 14 |
39 |
KCNA4
| 2件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome | D10228
D10228
|
Amifampridine
| 3件: 3 3, 11, 12 |
40 |
KCNC3
| 1件: Spinocerebellar ataxia Spinocerebellar ataxia | D04127
D04127
|
Dalfampridine
| 5件: 3 3, 4, 6, 13, 14 |
41 |
KCNC3
| 1件: Spinocerebellar ataxia Spinocerebellar ataxia | D10228
D10228
|
Amifampridine
| 3件: 3 3, 11, 12 |
42 |
KCND2
| 1件: Serotonergic synapse Serotonergic synapse | D04127
D04127
|
Dalfampridine
| 5件: 3 3, 4, 6, 13, 14 |
43 |
KCND2
| 1件: Serotonergic synapse Serotonergic synapse | D10228
D10228
|
Amifampridine
| 3件: 3 3, 11, 12 |
44 |
KCND3
| 1件: Spinocerebellar ataxia Spinocerebellar ataxia | D04127
D04127
|
Dalfampridine
| 5件: 3 3, 4, 6, 13, 14 |
45 |
KCND3
| 1件: Spinocerebellar ataxia Spinocerebellar ataxia | D10228
D10228
|
Amifampridine
| 3件: 3 3, 11, 12 |
46 |
GABRQ
| 5件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00550
D00550
|
Midazolam
| 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 272, 298, 299 |
47 |
PTGS1
| 5件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes | D00217
D00217
|
Acetaminophen
| 15件: 3 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 222, 256, 271, 337 |
48 |
PTGS2
| 22件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer | D00217
D00217
|
Acetaminophen
| 15件: 3 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 222, 256, 271, 337 |
49 |
PTGS2
| 22件: Arachidonic acid metabolism Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer | D00567
D00567
|
Celecoxib
| 10件: 2 2, 3, 34, 46, 70, 89, 107, 161, 171, 271 |
50 |
RRM2
| 7件: Purine metabolism Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, p53 signaling pathway | D00341
D00341
|
Hydroxyurea
| 8件: 3 3, 13, 19, 20, 65, 85, 86, 284 |
51 |
SMN1
| - | D11559
D11559
|
Onasemnogene abeparvovec
| 1件: 3 3 |
52 |
SMN2
| - | D10881
D10881
|
Nusinersen
| 1件: 3 3 |
53 |
SMN2
| 1件: Nucleocytoplasmic transport Nucleocytoplasmic transport | D11406
D11406
|
Risdiplam
| 1件: 3 3 |
54 |
SMN2
| - | D12272
D12272
|
Branaplam
| 2件: 3 3, 8 |
55 |
TNNC2
| 1件: Calcium signaling pathway Calcium signaling pathway | D11363
D11363
|
Reldesemtiv
| 1件: 3 3 |
56 |
ALDH5A1
| 3件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Butanoate metabolism, Metabolic pathways | D00399
D00399
|
Valproic acid
| 14件: 2 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256 |
57 |
CACNA1I
| 7件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome | D00399
D00399
|
Valproic acid
| 14件: 2 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256 |
58 |
CACNA1H
| 7件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome | D00399
D00399
|
Valproic acid
| 14件: 2 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256 |
59 |
CACNA1G
| 8件: MAPK signaling pathway MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome | D00399
D00399
|
Valproic acid
| 14件: 2 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256 |